Amarin (AMRN) Shares Ramp Higher Following Publication of New Vascepa Phase 3 Data
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp. (Nasdaq AMRN) shares are ticking higher after updatng on its MARINE Phase 3 for vascepa.
Amarin said the drug met primary efficacy endpoints and "significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles."
Shares are up about 3 percent in late trading Tuesday.
Amarin said the drug met primary efficacy endpoints and "significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles."
Shares are up about 3 percent in late trading Tuesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Samsung Plans As Much As $79 Billion In Shareholder Returns - Bloomberg
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
